Feinberg Peter

Director Feinberg bought 20,000 shares of IMRX at $4.35 on 2026-01-12; stock down 52.2% from 52-week high, post-transaction holdings 135,441 shares.

Peter Feinberg, a Director at Immuneering Corp, purchased 20,000 shares at $4.35 on 2026-01-12, expanding his holdings from 115,441 to 135,441 shares. The purchase occurred in a context of significant price pressure: the stock trades at $4.43, down 52.2% from the 52-week high and 23.4% over the past 30 days. At this ticker, Feinberg's prior five trades show mixed outcomes—his June 2025 purchase appreciated 228.8% at the 90-day mark, but his March 2024 and September 2025 purchases suffered declines; overall, 1 of 5 prior IMRX trades were well-timed at the 90-day mark. Fundamentally, the company faces headwinds: latest quarterly revenue is $0.00, net income is $-14,964,875.00, and annual revenue growth is -100.0%, indicating a material deterioration in the business profile. The buy signal from insider accumulation is notably weakened by both the weak execution track record at this specific ticker and the company's fundamental contraction.

Director Peter Feinberg buys 7,500 shares of IMRX at $6.67; stake rises 5.0% amid cluster buying by 3 other insiders.

Feinberg purchased 7,500 shares (7.5K shares) at $6.67 on 2025-10-03, increasing his holdings to 156,766 shares (156.8K shares), a 5.0% increase from his prior position. This buy occurs as part of a cluster of activity—3 other insiders also bought within the past 14 days—which often signals coordinated confidence in valuation or forward direction. However, context is mixed: the stock currently trades at $6.11, down 34.0% from its 52-week high of $9.26, though it has gained 10.9% over the past 30 days and 37.3% over 90 days. At the same ticker, Feinberg's prior trade outcomes have been inconsistent—a June 2025 buy returned 228.8% at the 90-day mark, but March 2024 buys returned -44.7% and -40.0% at 90 days, and he has achieved only a 1-of-3 well-timed rate on his IMRX trades. Fundamentally, the company reported zero revenue in its latest quarter, posted a net loss of $14,433,881.00 ($-14.4M) on an annual basis, with -100.0% annual revenue growth, and maintains a $158,481,571.04 ($158.5M) market cap. The combination of cluster buying activity and the director's willingness to accumulate despite deteriorating financials invites closer scrutiny of whether this reflects a positive forward view or is disconnected from underlying business performance.

Director Feinberg buys 7,500 shares of IMRX at $7.03 as part of cluster pattern; stock now -31.3% from 52-week high

Peter Feinberg, a Director, purchased 7,500 shares at $7.03 on 2025-09-30, bringing his holdings to 149,266 shares (+5.3% from pre-transaction level). This buy occurred as part of a cluster pattern, with 3 other insiders also purchasing within the past 14 days. The timing is notable given current price of $6.36 is -31.3% from the 52-week high, though IMRX has rallied +84.4% over 90 days and +10.6% over 30 days. Feinberg's prior trades at IMRX show mixed results: his June 2025 buy delivered +228.8% over 90 days, but his March 2024 cluster of three buys each underperformed with 90-day returns ranging from -34.5% to -44.7%. The company remains unprofitable with $-14,433,881 net loss and zero quarterly revenue, creating fundamental headwinds that offset the concurrent insider buying momentum.

Director Feinberg buys 5,000 shares of IMRX at $7.18; price now at $7.00, -24.4% from 52-week high.

Peter Feinberg, a director at Immuneering Corp, purchased 5,000 shares at $7.18 on 2025-09-29, increasing his holdings to 141.8K shares. The stock has recently gained +21.7% over 30 days and +95.0% over 90 days, though it remains -24.4% below its 52-week high of $9.26. However, the company's fundamentals are severely challenged: it reported $0.00 revenue in the latest quarter, a net loss of $-14.4M annually, and -100.0% annual revenue growth, indicating a pre-revenue or stalled-revenue stage business with substantial ongoing losses. Feinberg's prior trades at IMRX show mixed results: one exceptional win (buy on 2025-06-18 returned +228.8% in 90 days) offset by three significant losses in March 2024 (90-day returns ranged from -40.0% to -44.7%), and his cross-ticker track record shows only a 20.00% 90-day win rate. The confluence of acute financial stress and recent share accumulation at a modestly elevated price warrants scrutiny of whether this reflects selective opportunism or execution challenges in a distressed name.

Director Feinberg buys 25,000 IMRX shares at $2.53; 0 of 4 prior IMRX buys showed positive 90d returns.

Peter Feinberg, a Director, purchased 25,000 shares of Immuneering at $2.53 on 2025-06-18, increasing his holdings from 111.8K to 136.8K shares (+22.4%). This purchase comes amid rising stock momentum: IMRX has climbed 58.4% over the prior 30 days and 44.4% over 90 days, placing it 24.0% below its 52-week high of $3.21. However, Feinberg's prior trading history at this ticker is unambiguously negative: in 4 prior purchases at IMRX (March 2024), each incurred substantial 90-day losses ranging from -34.5% to -50.6%, with 0 of 4 posts showing positive 90-day returns. The company remains unprofitable with latest-quarter revenue at $0.00 and full-year net income of $-15,046,132.00. Additionally, 4 other insiders bought within the past 14 days, establishing a cluster pattern. The confluence of poor historical timing at this specific ticker, ongoing fundamental weakness, and current valuation context relative to Feinberg's prior purchases raises questions about whether recent price momentum justifies accumulation.